Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

References

• Matzinger P. The danger model: a renewed sense of self. Science296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev.173, 89–97 (2000).
   PubMed Web of Science ®Google Scholar
• Ramon G. Sur L’augmentation anormale de L’antitoxine chez les chevaux producteurs de serum antidiphtherique. Bull. Soc. Centr. Med. Vet.101, 227–234 (1925).
   Google Scholar
• Warshakoon HJ, Hood JD, Kimbrell MR et al. Potential adjuvantic properties of innate immune stimuli. Hum. Vaccin.5(6), 381–394 (2009).
   PubMed Web of Science ®Google Scholar
• Richou R, Jensen R, Belin C. Research on saponin, an adjuvant substance which stimulates immunity. I. Rev. Immunol. Ther. Antimicrob.28, 49–62 (1964).
   PubMedGoogle Scholar
• Egerton JR, Laing EA, Thonley CM. Effect of Quil A, a saponin derivative, on the response of sheep to alum precipitated bacteroidesnodosus vaccine. Vet. Sci. Commun.2, 247–252 (1978).
   Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature308(5958), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine27(12), 1787–1796 (2009).
   PubMed Web of Science ®Google Scholar
• Soltysik S, Wu J-Y, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine13(15), 1403–1410 (1995).
   PubMed Web of Science ®Google Scholar
• Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Relationship between adjuvant activity and amphipathic structure of soyasaponins. Vaccine21(17–18), 2145–2151 (2003).
   PubMed Web of Science ®Google Scholar
• Rhodes J. Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation. J. Immunol.143(5), 1482–1489 (1989).
   PubMed Web of Science ®Google Scholar
• Marciani DJ, Press JB, Reynolds RC et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine18(27), 3141–3151 (2000).
   PubMedGoogle Scholar
• Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1–KLH and GD3–KLH conjugates. Vaccine19(4–5), 530–537 (2000).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl Acad. Sci. USA84(9), 2911–2915 (1987).
   PubMed Web of Science ®Google Scholar
• Helling F, Zhang S, Shang A et al. GM2–KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res.55(13), 2783–2788 (1995).
   PubMed Web of Science ®Google Scholar
• Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine12(14), 1275–1280 (1994).
   PubMed Web of Science ®Google Scholar
• Waite DC, Jacobson EW, Ennis FA et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine19(28–29), 3957–3967 (2001).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Livingston PO, Hood C et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res.9(14), 5214–5220 (2003).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer85(5), 659–666 (2000).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res.6(5), 1693–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Ragupathi G, Bhuta S et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a Phase I trial. Proc. Natl Acad. Sci. USA98(6), 3270–3275 (2001).
   PubMed Web of Science ®Google Scholar
• Gilewski TA, Ragupathi G, Dickler M et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res.13(10), 2977–2985 (2007).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Fernandez C et al. A polyvalent vaccine for high-risk prostate patients: “are more antigens better?”. Cancer Immunol. Immunother.56(12), 1921–1930 (2007).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Musselli C et al. Thomsen–Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother.54(7), 694–702 (2005).
   PubMed Web of Science ®Google Scholar
• Slovin SF, Ragupathi G, Musselli C et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol.21(23), 4292–4298 (2003).
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res.13(14), 4170–4177 (2007).
   PubMed Web of Science ®Google Scholar
• Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res.5(10), 2773–2779 (1999).
   PubMed Web of Science ®Google Scholar
• Krug LM, Ragupathi G, Hood C et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res.10(18 Pt 1), 6094–6100 (2004).
   PubMed Web of Science ®Google Scholar
• Krug LM, Ragupathi G, Ng KK et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin. Cancer Res.10(3), 916–923 (2004).
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Randomized Phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J. Clin. Oncol.28(15 Suppl.), (2010) (Abstract 8505).
   Google Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res.10(5), 1670–1677 (2004).
   PubMed Web of Science ®Google Scholar
• Evans TG, McElrath MJ, Matthews T et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine19(15–16), 2080–2091 (2001).
   PubMed Web of Science ®Google Scholar
• Kashala O, Amador R, Valero MV et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine20(17–18), 2263–2277 (2002).
   PubMed Web of Science ®Google Scholar
• Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med.359(24), 2533–2544 (2008).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine26(10), 1375–1386 (2008).
   PubMed Web of Science ®Google Scholar
• Cleland JL, Kensil CR, Lim A et al. Isomerization and formulation stability of the vaccine adjuvant QS-21. J. Pharm. Sci.85(1), 22–28 (1996).
   PubMedGoogle Scholar
• Drane D, Gittleson C, Boyle J Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines6(5), 761–772 (2007).
   PubMed Web of Science ®Google Scholar
• Martín R, Briones R. Industrial uses and sustainable supply of Quillaja saponaria (rosaceae) saponins. Econ. Bot.53(3), 302–311 (1999).
   Web of Science ®Google Scholar
• Kamstrup S, San Martin R, Doberti A, Grande H, Dalsgaard K. Preparation and characterisation of Quillaja saponin with less heterogeneity than Quil-A. Vaccine18(21), 2244–2249 (2000).
   PubMedGoogle Scholar
• Martin RS Briones R. Quality control of commercial Quillaja (Quillaja saponaria Molina) extracts by reverse phase HPLC. J. Sci. Food Agriculture80, 2063–2068 (2000).
   Web of Science ®Google Scholar
• Yu B, Zhang Y, Tang P. Carbohydrate chemistry in the total synthesis of saponins. European J. Org. Chem.2007(31), 5145–5161 (2007).
   Google Scholar
• Zhu X, Yu B, Hui Y, Higuchi R, Kusano T, Miyamoto T. Synthesis and absolute stereochemistry of the acyl moiety of Quillaja saponins. Tetrahedron Lett.41(5), 717–719 (2000).
   Google Scholar
• Zhu X, Yu B, Hui Y, Schmidt RR. Synthesis of the trisaccharide and tetrasaccharide moieties of the potent immunoadjuvant QS-21. Eur. J. Org. Chem.2004(5), 965–973 (2004).
   Google Scholar
• Kim YJ, Wang P, Navarro-Villalobos M, Rohde BD, Derryberry J, Gin DY. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J. Am. Chem. Soc.128(36), 11906–11915 (2006).
   PubMed Web of Science ®Google Scholar
• Wang P, Kim YJ, Navarro-Villalobos M, Rohde BD, Gin DY. Synthesis of the potent immunostimulatory adjuvant QS-21A. J. Am. Chem. Soc.127(10), 3256–3257 (2005)
   PubMed Web of Science ®Google Scholar
• Deng K, Adams MM, Damani P, Livingston PO, Ragupathi G, Gin DY. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine. Angew. Chem. Int. Ed. Engl.47(34), 6395–6398 (2008).
   PubMed Web of Science ®Google Scholar
• Ragupathi G, Damani P, Deng K et al. Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins. Vaccine28(26), 4260–4267 (2010).
   PubMedGoogle Scholar
• Adams MM, Damani P, Perl NR et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J. Am. Chem. Soc.132(6), 1939–1945 (2010).
   PubMed Web of Science ®Google Scholar